Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2021)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2021-06-07
Court	District Court, D. Massachusetts	Date Terminated	2023-11-28
Cause	35:271 Patent Infringement	Assigned To	Allison Dale Burroughs
Jury Demand	Plaintiff	Referred To
Parties	ELI LILLY AND COMPANY
Patents	10,392,434
Attorneys	Andrew S. McDonough
Firms	Finnegan Henderson Farabow Garrett and Dunner
Link to Docket	External link to docket

The biologic drug covered by the patent cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2021-06-08	1	Complaint	United States patent in the same family as the Patents-in-Suit, U.S. Patent No. 10,392,434 (“the ʼ434 patent…U.S. Patent Nos. 11,028,160 and 11,028,161 (respectively, “the ʼ160 patent” and “the ʼ161 patent”) (together… patent”). On their face, both of the Patents-in-Suit claim priority to the ʼ434 patent. Exs 1, 2. And…in Eli Lilly’s U.S. Patent No. 9,505,838 (“the ʼ838 patent”). Ex. 24 (ʼ838 patent). The amino acid sequences…(together, “the Patents-in- Suit”). The applications that issued as the Patents-in-Suit were assigned	External link to document
2023-11-22	67	Stipulation of Dismissal	United States Patent Nos. 11,028,160 (“the ʼ160 patent”) and 11,028,161 (“the ʼ161 patent”, and together…to the ʼ160 patent, IPR2022-00738; the ʼ161 patent, IPR2022-00739; and United States Patent No. 10,392,434…10,392,434 (“the ʼ434 patent,” and together with the Patents-in-Suit, the “Teva Patents”), IPR2022-00796 … the Teva Patents or any other United States patent, patent application, continuation,…together with the ʼ160 patent, the “Patents- in-Suit”); WHEREAS Lilly filed for inter partes review	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document